Premixed Human Isophane Insulin Suspension + Human Insulin Injection
Drugpremixed human insulin
Other names: premixed human insulin
NCT Number: NCT04726657
Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
A cross-over study of 36 well controlled people with type 2 Diabetes Mellitus who underwent 7-day Continuous Glucose Monitoring with Premixed Human Insulin 30/70 and subsequently with Biphasic Aspart 30.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
premixed human insulin
Other names: premixed human insulin
Premixed Insulin Analog Biphasic Aspart 30
Other names: Biphasic Aspart 30
Time frame: 7 days
average blood glucose (mg/dl) from continuous glucose monitoring
Time frame: 7 days
levels of glycated albumin (%) in serum
Time frame: 7 days
levels of fructosamine (μmol/L) in serum
Time frame: 7 days
change in total daily dose of insulin (u)
Time frame: 7 days
change in nocturnal average blood glucose
Time frame: 7 days
change in time in range (% and minutes) from continuous glucose monitoring
Time frame: 7 days
change in time above 180 (% and minutes) from continuous glucose monitoring
Time frame: 7 days
change in time below 70 (% and minutes) from continuous glucose monitoring
Aristotle University Of Thessaloniki
Other
Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05259449
Diabetes Mellitus, Diabetes Mellitus, Type 2
Puerto Real, Cadiz, Spain
View Trial DetailsNCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial DetailsNCT00340132
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT06186102
Arterial Occlusive Diseases, Arteriosclerosis
Aarhus, Jutland, Denmark
View Trial Details